| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SFTPA1 |
| Uniprot No | Q8IWL2 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 21-248aa |
| 氨基酸序列 | EVKDVCVGSPGIPGTPGSHGLPGRDGRDGLKGDPGPPGPMGPPGEMPCPPGNDGLPGAPGIPGECGEKGEPGERGPPGLPAHLDEELQATLHDFRHQILQTRGALSLQGSIMTVGEKVFSSNGQSITFDAIQEACARAGGRIAVPRNPEENEAIASFVKKYNTYAYVGLTEGPSPGDFRYSDGTPVNYTNWYRGEPAGRGKEQCVEMYTDGQWNDRNCLYSRLTICEF |
| 预测分子量 | 31.1 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于SFTPA1重组蛋白的3-4篇参考文献示例(内容为示例，建议通过学术数据库验证原文)：
1. **文献名称**：*"Recombinant human surfactant protein A1 suppresses LPS-induced lung inflammation via modulation of NF-κB signaling"*
**作者**：Kuroki Y, et al.
**摘要**：研究重组人SFTPA1蛋白通过抑制NF-κB通路减轻脂多糖(LPS)诱导的小鼠肺部炎症，证实其在调节先天免疫反应中的作用。
2. **文献名称**：*"Expression and functional characterization of recombinant SFTPA1 in a mammalian cell system"*
**作者**：Wang L, et al.
**摘要**：报道在哺乳动物细胞系统中成功表达功能性重组SFTPA1.并验证其结合病原体相关分子模式(PAMPs)的能力，提示其在宿主防御中的应用潜力。
3. **文献名称**：*"Structural determinants of surfactant protein A1 function in bacterial agglutination and immune modulation"*
**作者**：McCormack FX, et al.
**摘要**：通过重组SFTPA1的结构分析，揭示其胶原样结构域和碳水化合物识别域对细菌凝集和巨噬细胞激活的关键作用。
4. **文献名称**：*"Therapeutic efficacy of recombinant SFTPA1 in a murine model of Pseudomonas aeruginosa pneumonia"*
**作者**：Garcia-Verdugo I, et al.
**摘要**：在小鼠铜绿假单胞菌肺炎模型中，重组SFTPA1显著降低细菌负荷和肺损伤，证明其作为治疗性蛋白的潜力。
建议使用PubMed或Google Scholar搜索关键词**"recombinant SFTPA1"**或**"surfactant protein A1 expression"**获取具体文献。
Surfactant Protein A1 (SFTPA1) is a critical member of the collectin family, primarily synthesized and secreted by alveolar type II cells in the lungs. It plays a dual role in pulmonary homeostasis: stabilizing surfactant lipids to reduce alveolar surface tension and modulating innate immune responses. Structurally, SFTPA1 contains a collagen-like domain and a carbohydrate recognition domain (CRD), enabling it to bind pathogens, allergens, and apoptotic cells while interacting with immune cells like macrophages to regulate phagocytosis and inflammation. Genetic mutations in SFTPA1 are linked to idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases, highlighting its importance in lung health.
Recombinant SFTPA1 (rSFTPA1) is produced using expression systems such as mammalian cells (e.g., HEK293 or CHO cells) or bacteria (E. coli), with mammalian systems preferred for proper post-translational modifications. Purification typically involves affinity chromatography and quality control assays to confirm functional integrity. Research applications include studying its role in host-pathogen interactions, immune regulation, and surfactant dynamics, as well as exploring therapeutic potential in acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease (COPD), or as an anti-inflammatory agent. Challenges in therapeutic use involve optimizing bioavailability and delivery methods. Overall, rSFTPA1 serves as a vital tool for dissecting pulmonary biology and developing targeted lung therapies.
×
